Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Orexo Interim Report Q4 2023, incl. Full Year Report | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
By: PR Newswire Association LLC. - 08 Feb 2024 | Back to overview list |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
UPPSALA, Sweden, Feb. 8, 2024 /PRNewswire/ -- Positive EBITDA in H2 setting the target for FY 2024 Q4 2023 highlights
Important events after the end of the period
Financial outlook 2024
The financial outlook 2024 is based on a forward looking assumption of a USD/SEK exchange rate of 10.28 calculated Strong recovery in financial results and FDA initiated the review of OX124 CEO Comments in brief "I am pleased to report a Q4 result delivering a positive EBITDA and strong Zubsolv® net sales both compared to Q4 2022 and Q3 2023. Zubsolv net sales year over year grew more than 6 percent in both SEK and USD, and nearly 8 percent quarter over quarter. I am also delighted to share that we are continuing to drive efficiencies across the business and have reduced operating expenses by 23 percent from last year. This recovery in financial performance is not driven by exchange rates, on the contrary, our EBITDA in H2 would have been nearly SEK 8 million higher if we had applied the exchange rates from end of 2022. I am also pleased to announce that we, despite currency headwinds, reached our financial guidance for 2023, and in particular the positive EBITDA for H2. With relatively stable exchange rates and no other extraordinary events in 2024, we are confident we can reach a positive EBITDA for the FY 2024." To read the full CEO Comments view attached PDF. Contact persons quarterly report Presentation To attend via teleconference where you can ask questions verbally: When registered you will be provided phone numbers and a conference ID to access the conference. To attend via webcast: Prior to the call, presentation material will be available on the website under Investors/Reports/Audiocasts. This information is information that Orexo AB (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact persons set out above at 8 am CET on February 8, 2024. The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/orexo-interim-report-q4-2023-incl-full-year-report-302057222.html |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |